



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
July 16, 2025**

Therapeutic Class	Drug Name	DURB Recommendation*
Hemophilia Treatments		
	<i>Alhemo (Subcutaneous) Solution</i> <i>Hympavzi (Subcutaneous) Solution</i>	Defer to October 2025 DUR Board Meeting
Transthyretin Agents		
	<i>Attruby (Oral) Tablet</i>	P/PA
Neuropathic Pain and Select Agents		
	<i>Journavx (Oral) Tablet</i>	P/PA
Antihypertensive Agents		
	<i>Tryvio (Oral) Tablet</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'
Administered Drug List